Spravato FAQs
What is Spravato?
Spravato (esketamine) is an FDA-approved prescription drug delivered as a nasal spray to be used with and without an antidepressant taken by mouth to treat adults diagnosed with treatment-resistant depression (TRD) or with an antidepressant taken by mouth to treat the symptoms of major depressive disorder (MDD) with suicidal thoughts or behaviors. It is a derivative of ketamine and works differently than traditional antidepressants by targeting NMDA receptors in the brain.
Some patients report noticeable improvement in depressive symptoms within hours or days of starting treatment. However, response times vary, and multiple doses may be needed to achieve significant benefits.
No. Due to the sedative and dissociative effects, patients are advised not to drive or operate heavy machinery until the following day after a full night’s sleep.
Many insurance plans, including Medicare and Medicaid, cover Spravato for eligible patients. However, coverage varies by provider, and prior authorization may be required. Patients should check with their insurance company for details.
The duration of treatment depends on individual response and the severity of depression. Some patients continue maintenance treatments, while others may transition off Spravato under their doctor’s guidance.
Spravato has a potential for misuse due to its similarities to ketamine. However, it is administered under strict medical supervision in certified clinics, reducing the risk of misuse or addiction.
If you miss a scheduled dose, contact your healthcare provider to determine the best course of action. Consistency in treatment is important for optimal results.
Unlike traditional antidepressants, which can take weeks to show effects, Spravato may provide faster relief for severe depression. It is often used when other medications have failed to provide adequate improvement.
Spravato is only available at certified healthcare facilities that follow the Risk Evaluation and Mitigation Strategy (REMS) program guidelines. Patients must take it under supervision in an approved treatment center.
If you have questions about Spravato treatment, schedule a consultation with the psychiatric experts at Empire State Psychiatry. Widely regarded as one of the top providers of esketamine-based therapies in New York City, Empire State Psychiatry is committed to delivering expert, patient-centered care. Their office is located in Midtown Manhattan, and they serve patients from the Upper East Side and surrounding New York City neighborhoods.